1 Min Read
June 1 (Reuters) - GenePOC Inc:
* Received 510(K) clearance from U.S. FDA to market first molecular assay to detect group B streptococcus & for Revogene molecular diagnostics instrument Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.